Entasis lands first antibiotic approval eight years after spinning out of AstraZeneca
Almost eight years after spinning out AstraZeneca’s antibiotics pipeline, Entasis Therapeutics has landed its first approval.
The FDA approved its Xacduro, made up of sulbactam and durlobactam injections, as a treatment for pneumonia caused by difficult-to-treat bacteria strains known as Acinetobacter baumannii-calcoaceticus complex (A. baumannii) among adult patients. Particularly among already vulnerable hospitalized patients, these infections can be deadly.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters